Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party.
Knop
S
S
Hebart
H
H
Gratwohl
A
A
Kliem
C
C
Faul
C
C
Holler
E
E
Apperley
J
J
Kolb
H J
HJ
Schaefer
A
A
Niederwieser
D
D
Einsele
H
H
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000276:immunology / Q000382:microbiology / Q000628:therapy; D016026:Bone Marrow Transplantation; D017252:CD3 Complex / Q000032:analysis; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D006086:Graft vs Host Disease / Q000382:microbiology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D007938:Leukemia / Q000150:complications / Q000628:therapy; D008223:Lymphoma / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D036102:Peripheral Blood Stem Cell Transplantation; D011446:Prospective Studies; D012074:Remission Induction; D013256:Steroids / Q000627:therapeutic use*
D017252:CD3 Complex; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D013256:Steroids